In the past decade, numerous tyrosine kinase inhibitors (TKIs) have been introduced in the treatment of chronic myeloid leukemia. Given the significant interpatient variability in TKIs pharmacokinetics, potential drug-drug interactions (DDIs) can greatly impact patient therapy. This review aims to discuss the pharmacokinetic characteristics of TKIs, specifically focusing on their absorption, distribution, metabolism, and excretion profiles. Additionally, it provides a comprehensive overview of the utilization of TKIs in special populations such as the elderly, children, and patients with liver or kidney dysfunction. We also highlight known or suspected DDIs between TKIs and other drugs, highlighting various clinically relevant interactions. Moreover, specific recommendations are provided to guide haemato-oncologists, oncologists, and clinical pharmacists in managing DDIs during TKI treatment in daily clinical practice.

中文翻译：

---

酪氨酸激酶抑制剂在慢性粒细胞白血病中的临床药代动力学和药物相互作用：临床视角

在过去的十年中，许多酪氨酸激酶抑制剂（TKI）被引入治疗慢性粒细胞白血病。鉴于 TKI 药代动力学存在显着的患者间差异，潜在的药物相互作用 (DDI) 可能会极大地影响患者的治疗。本综述旨在讨论 TKI 的药代动力学特征，特别关注其吸收、分布、代谢和排泄特征。此外，它还全面概述了 TKI 在老年人、儿童和肝肾功能不全患者等特殊人群中的使用情况。我们还强调 TKI 与其他药物之间已知或可疑的 DDI，强调各种临床相关的相互作用。此外，还提供了具体建议来指导血液肿瘤学家、肿瘤学家和临床药剂师在日常临床实践中 TKI 治疗期间管理 DDI。